US4665058A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compositions and method of treatment for sickle cell anemia
Assignee: KENTUCKY RESEARCH FOUNDATION A CORP OF KENTUCKY, University of
•
Filing: 1985-03-16
•
Granted: 1987-05-12
•
Expires: 2005-03-16
Abstract
Abstract The invention provides a new composition and method for the treatment of sickle cell anemia. The composition includes as an active ingredient an effective amount of the compound, phlorizin benzylazide: <IMAGE> and an appropriate pharmaceutical excipient. Load and maintenance dosage ranges as well as effective blood concentration levels for the active ingredient are disclosed.
Inventors
- 👤 Donald F. Diedrich
- 👤 Christopher L. Maynard
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 22:16
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/7004; C; C07; C07H; C07H17/00; C07H17/04; C07H17/06; C07H17/065; C07H17/07
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
24 words
A pharmaceutical composition for use in the treatment of sickle cell anemia patients comprising as an active ingredient an effective amount of phlorizin benzylazide.
Claim 2
Dependent Claim
24 words
A pharmaceutical composition for use in the treatment of sickle cell anemia patients comprising as an active ingredient an effective amount of phlorizin benzylazide.
Claim 3
Dependent Claim
19 words
The composition set forth in claim 1, including a pharmaceutical excipient so as to be adapted for administration parenterally.
Claim 4
Dependent Claim
23 words
The composition set forth in claim 1, in load dosage form including from 0.5-1.0 mg of active ingredient per kilogram of the patient.
Claim 5
Dependent Claim
23 words
The composition set forth in claim 3, wherein said load dosage is approximately 0.75 mg of active ingredient per kilogram of the patient.
Claim 6
Dependent Claim
27 words
The composition set forth in claim 1, in maintenance dosage form including from 0.05 to 0.2 mg of active ingredient per kilogram of the patient per day.
Claim 7
Dependent Claim
25 words
The composition set forth in claim 5, wherein said maintenance dosage is approximately 0.125 mg of active ingredient per kilogram of the patient per day.
Claim 8
Dependent Claim
30 words
The composition set forth in claim 1, wherein said effective amount of said active ingredient is approximately a 6-12.5 μM concentration of phlorizin benzylazide in the blood of the patient.
Claim 9
Independent Claim
24 words
A method for the treatment of sickle cell anemia in a patient comprising administering to the patient an effective dosage amount of phlorizin benzylazide.
Claim 10
Independent Claim
24 words
A method for the treatment of sickle cell anemia in a patient comprising administering to the patient an effective dosage amount of phlorizin benzylazide.
Claim 11
Dependent Claim
23 words
The method of claim 8 wherein said effective dosage amount of phlorizin benzylazide is administered parenterally in a pharmaceutical excipient as a composition.
Claim 12
Dependent Claim
28 words
The method of claim 8, including the step of administering a load dosage to the patient of from 0.5-1.0 mg of phlorizin benzylazide per kilogram of the patient.
Claim 13
Dependent Claim
21 words
The method of claim 10, wherein said load dosage is approximately 0.75 mg of phlorizin benzylazide per kilogram of the patient.
Claim 14
Dependent Claim
32 words
The method of claim 8, including the step of administering a maintenance dosage to the patient of from 0.05 to 0.2 mg of phlorizin benzylazide per kilogram of the patient per day.
Claim 15
Dependent Claim
23 words
The method of claim 12, wherein said maintenance dosage is approximately 0.125 mg of phlorizin benzylazide per kilogram of the patient per day.
Claim 16
Dependent Claim
28 words
The method of claim 8, including the step of maintaining a phlorizin benzylazide concentration of approximately 6-12.5 μM in the blood of the patient to inhibit cell sickling.
References Cited (Backward Citations)
US3833724A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-05-11 | 1990-11-10 | 1991-05-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-05-11 | 1994-11-10 | 1995-05-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-05-11 | 1998-11-10 | 1999-05-12 | $7700.00 | Window Closed / Lapsed |